GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
NCT06310382
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
110
Enrollment
OTHER
Sponsor class
Conditions
Advanced Solid Tumors With MAPK Signal Pathway Mutations
Interventions
DRUG:
GH55
Sponsor
Suzhou Genhouse Bio Co., Ltd.
Collaborators
[object Object]
[object Object]